EUVIMEDEUVIMED entdecken
Crossref

Review of the CHA₂DS₂-VA Score

Simon Kraler

Evidence to Action: Official Journal of MDCalc · 10.06.2026 · 022026 (01)

DOI: 10.65357/001c.162500 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Evidence to Action: Official Journal of MDCalc, online erschienen am 10.06.2026. Verfasst von Simon Kraler.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The CHA₂DS₂-VASc score is a validated clinical tool for estimating the annual risk of thromboembolic events, including ischaemic stroke in patients with atrial fibrillation (AF). The novel CHA₂DS₂-VA score is a simplified, sex-neutral tool, endorsed by the European Society of Cardiology (ESC) guidelines for the management of AF patients 2024, for assessing the risk of adverse events (i.e., mortality, stroke, arterial thromboembolism) in AF patients. In the derivation cohort, women had similar adjusted risks of stroke or arterial thromboembolism as compared to men, with sex adding no predictive value for the primary endpoint. In fact, CHA₂DS₂-VA showed similar (i.e., non-inferior) performance to CHA₂DS₂-VASc with no interaction with sex, supporting the removal of sex to improve clinical usability. Limitations of the study by Champsi et al. include the use of a composite primary endpoint (mortality, stroke, arterial thromboembolism), which may obscure differences in individual outcomes, and the exclusion of patients aged ≥75 years, limiting generalizability to older populations. Moreover, patients with a history of previous stroke were excluded from the above study, with prior stroke representing an important determinant of ischaemic risk. Pending additional validation studies, CHA₂DS₂-VA can guide oral anticoagulation decisions, recommending OAC for scores ≥2 (Class I, Level C; ESC guidelines 2024) and considering it for a score of 1 (Class IIa, Level C; ESC guidelines 2024) through shared decision-making, considering patient preferences, individual bleeding risk (and proper management thereof if modifiable), and potential contraindications. Note that, in contrast to the ESC, most recent AHA/ASA guidelines do not yet recommend the use of the CHA₂DS₂-VA score.

Zitieren

APA

Kraler, S. (2026). Review of the CHA₂DS₂-VA Score. Evidence to Action: Official Journal of MDCalc, 022026(01). https://doi.org/10.65357/001c.162500

Vancouver

Kraler S. Review of the CHA₂DS₂-VA Score. Evidence to Action: Official Journal of MDCalc. 2026;022026(01). doi:10.65357/001c.162500

BibTeX
@article{Kraler2026,
  author = {Kraler, Simon},
  title = {Review of the CHA₂DS₂-VA Score},
  journal = {Evidence to Action: Official Journal of MDCalc},
  year = {2026},
  volume = {022026},
  number = {01},
  doi = {10.65357/001c.162500}
}
Kostenlos starten →